Resolvin D1 ameliorates Inflammation-Mediated Blood-Brain Barrier Disruption After Subarachnoid Hemorrhage in rats by Modulating A20 and NLRP3 Inflammasome

Inflammation is typically related to dysfunction of the blood-brain barrier (BBB) that leads to early brain injury (EBI) after subarachnoid hemorrhage (SAH). Resolvin D1 (RVD1), a lipid mediator derived from docosahexaenoic acid, possesses anti-inflammatory and neuroprotective properties. This study investigated the effects and mechanisms of RVD1 in SAH. A Sprague-Dawley rat model of SAH was established through endovascular perforation. RVD1was injected through the femoral vein at 1 and 12 h after SAH induction. To further explore the potential neuroprotective mechanism, a formyl peptide receptor two antagonist (WRW4) was intracerebroventricularly administered 1 h after SAH induction. The expression of endogenous RVD1 was decreased whereas A20 and NLRP3 levels were increased after SAH. An exogenous RVD1 administration increased RVD1 concentration in brain tissue, and improved neurological function, neuroinflammation, BBB disruption, and brain edema. RVD1 treatment upregulated the expression of A20, occludin, claudin-5, and zona occludens-1, as well as downregulated nuclear factor-κBp65, NLRP3, matrix metallopeptidase 9, and intercellular cell adhesion molecule-1 expression. Furthermore, RVD1 inhibited microglial activation and neutrophil infiltration and promoted neutrophil apoptosis. However, the neuroprotective effects of RVD1 were abolished by WRW4. In summary, our findings reveal that RVD1 provides beneficial effects against inflammation-triggered BBB dysfunction after SAH by modulating A20 and NLRP3 inflammasome.


INTRODUCTION
Subarachnoid hemorrhage (SAH) is a severe life-threatening acute cerebrovascular disease with a high rate of mortality and disability (Macdonald and Schweizer, 2017;Zhang et al., 2018). Increasing research suggests that early brain injury (EBI) occurring within 72 h of SAH is responsible for the disease prognosis W. Xu et al., 2019a). However, the exact mechanism of EBI after SAH remains unclear, and there is a lack of effective therapeutic agents. Inflammation and blood-brain barrier (BBB) disruption are thought to contribute to EBI (Sehba et al., 2012;Suzuki, 2015). Hence, reduction of inflammation and stabilization of the integrity of the BBB using pharmacological agents may attenuate EBI after SAH.
It is well known that maintenance of BBB integrity is essential for the regulation of central nervous system (CNS) homeostasis (Sweeney et al., 2019). An excessive inflammatory response disrupts the junctional complex in the BBB, leading to BBB dysfunction in several inflammatory CNS diseases, including trauma, Alzheimer's disease, and SAH (Chen et al., 2014;Bennett et al., 2020;Kim et al., 2020). The destroyed BBB allows peripheral neutrophils and other immune cells to infiltrate the CNS (Huang et al., 2020). Additionally, studies have confirmed that activated microglia and recruited neutrophils release various pro-inflammatory factors and exacerbate the inflammatory response after SAH (Ye et al., 2018;Tao et al., 2019).
The D-series of resolvin molecular family is derived from the metabolism of essential fatty acids, which play a critical role in orchestration of the resolution of inflammation and in restoration of tissue homeostasis (Chiang and Serhan, 2017). Resolvin D1 (RVD1), being one of the most crucial molecules in this family, has been shown to play a dual role in the inflammatory response, the roles being anti-inflammatory and pro-resolution in nature (Serhan et al., 2008). Specifically, RVD1 limits leukocyte infiltration, counter-regulates proinflammatory factors, and enhances macrophage efferocytosis and clearance of cellular debris (Duffield et al., 2006). Furthermore, RVD1 upregulates the expression of tight junction proteins and decreases vascular permeability in lipopolysaccharide-induced cultured human endothelial cells through the IκBα pathway (Zhang et al., 2013). This suggests that RVD1 inhibits inflammation-induced disruption of the BBB. However, whether RVD1 can ameliorate inflammation and BBB disruption after SAH and its specific mechanisms remain unclear.
Formyl peptide receptor 2 (FPR2), an endogenous receptor of RVD1, is a member of the formyl peptide receptor family (Dufton and Perretti, 2010), which are enriched in the CNS and play an important role in neuroinflammatory processes (Ho et al., 2018;R. Fusco et al., 2020a). Notably, FPR2 agonism often contributes to reducing inflammation in neurological disorders, such as in SAH (Dufton and Perretti, 2010;Guo et al., 2016). The nuclear factor (NF)-κB signaling pathway plays an important role in regulating inflammation by FPR2 . A20/tumor necrosis factor (TNF)-α-induced protein 3, also known as TNFAIP3, is a key molecule that inhibits NF-κB pathway activation by ubiquitination and exhibits significant antiinflammatory effects in various diseases (Wertz et al., 2004;Ma and Malynn, 2012;Lu et al., 2019). Additionally, it has been demonstrated that D-series of resolvin molecules inhibit NF-κB activation by upregulating A20 expression to produce anti-inflammatory effects (Sham et al., 2018). However, the precise role of A20 in EBI after SAH is unclear. NLRP3 inflammasome activation mediates caspase-1 cleavage and secretion of interleukin (IL)-18 and IL-1β, thereby contributing to the inflammatory response and cell death (R. Fusco et al., 2020b). Several studies have indicated that the NLRP3 inflammasome participates in the pathogenesis of multiple neurological diseases, including traumatic brain injury (Irrera et al., 2017), Alzheimer's disease (Heneka et al., 2013), and intracerebral hemorrhage (Ren et al., 2018). Moreover, emerging research has revealed that inhibition of NLRP3 inflammasome activation can reduce inflammatory responses and attenuate EBI during SAH Zhou et al., 2018). Recently, RVD1 was reported to mitigate tissue damage by inhibiting NLRP3 activation .
Based on the above-mentioned evidence, in the present study, we hypothesized that RVD1 protected the BBB by modulating A20 and NLRP3 to inhibit inflammation in a rat model of SAH.

Animals
A total of 279 male Sprague-Dawley rats (300-330 g) were purchased from the Laboratory Animal Center of the Southern Medical University (Guangzhou, China). Rats were kept in specific pathogen-free and humid conditions (12 h dark/light cycle). All experimental protocols complied with the requirements of the Southern Medical University Ethics Committee and the National Institutes of Health and Animal research guidelines.

SAH Model
SAH model was constructed by endovascular perforation of rats as per previously reported methods (Schwartz et al., 2000). Briefly, rats were randomly assigned to sham, sham + vehicle, sham + RVD1, SAH, SAH + vehicle, SAH + RVD1, and SAH + RVD1+WRW4 groups and anesthetized with pentobarbital sodium (dosage: 40 mg/kg, intraperitoneal administration). Dissection and exposition of the left carotid artery and its branch vessels were performed. A sharpened 4-0 single-strand nylon thread was inserted into the left internal carotid artery from the external carotid artery cut off, and then the terminal bifurcation of the left internal carotid artery was punctured, inducing SAH. Sham group rats underwent a similar operation without vessel perforation. The suture was maintained in the vessel for approximately 10 s and then removed.

Study Design
Three independent experiments were designed as described below. A total of 279 rats were used (Supplementary Figure  S1B, C).

Experiment 1
To identify the time course of expression of RVD1, FPR2, and A20 after SAH as well as the cellular localization of FPR2 and A20, rats were randomly divided into the following groups: sham and SAH after 6, 12, 24, 48, and 72 h. The endogenous RVD1 concentration was measured with enzyme-linked immunosorbent assay (ELISA) kits (Omnimabs, Alhambra, CA, United States) according to the manufacturer's instructions. Western blot analysis was performed to determine the changes in levels of FPR2 and A20 proteins. The cellular localization of FPR2 and A20 was determined by immunofluorescence (IF) co-staining.

Experiment 3
To investigate the underlying mechanism of the protective role of RVD1, the optimal dose (0.3 μg/kg) of RVD1 was selected based on the results of experiment 2. The rats were randomly distributed into four experimental groups, namely sham, SAH + vehicle, SAH + RVD1, and SAH + RVD1+WRW4. Neurological scores, BWC, IF staining, immunohistochemical staining, terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) staining, Fluoro-Jade C (FJC) staining, western blotting, and ELISA were performed at 24 or 72 h after SAH.

Intracerebroventricular Drug Injection
Intracerebroventricular administration was performed as per previously reported methods (Liu et al., 2019b). Rats were anesthetized with 3% isoflurane and positioned in a stereotaxic apparatus. First, the rat skull was exposed and drilled at the following coordinates relative to the bregma: posterior 1.0 mm, lateral 1.5 mm, and 4.0 mm below endplate of the skull. A 25-μL Hamilton Syringe (Microliter 702, Hamilton Company, Reno, NV, United States) was inserted into the left lateral ventricle. The needle was held in place for 5 min after injection and pulled out slowly after another 5 min. Finally, the burr hole was closed with bone wax and the incision was sutured.

Neurological Function Evaluation
Short-term neurological function was evaluated by an investigator who was blinded to the experimental protocol, using the modified Garcia scale and tests as per previously described methods (Garcia et al., 1995). The modified Garcia scale (maximum score of 18) assessed included touch of trunk, vibratory touch, spontaneous activity (0-3), spontaneous movements of four limbs (0-3), climbing capacity (1-3), and forelimbs stretching (0-3).
SAH grades were assessed blindly using the scoring system as per previously reported protocols (Sugawara et al., 2008). Rats with a grade <8 at 24 h after SAH were excluded from the study.

BWC Analysis
Brain edema was assessed by determining the BWC at 24 h after SAH. The rats were euthanized; brain tissues were collected and divided into the left hemisphere (LH), right hemisphere (RH), cerebellum (CB), and brain stem (BS), and their wet weight was measured immediately. The samples were placed in an oven at 100°C for 48 h. The dry weight of the samples was then measured. BWC was calculated with the following formula: [(wet weightdry weight)/wet weight] × 100%.

H and E Staining
H and E staining was performed as per previously described methods (Xie et al., 2015). Brain tissue was harvested and Frontiers in Pharmacology | www.frontiersin.org February 2021 | Volume 11 | Article 610734 immobilized in 4% paraformaldehyde for 24-48 h. Brain tissue was then embedded in paraffin and coronal serial slices were obtained (thickness of 4 μm/slice). The slices were stained, and images were captured under a light microscope.

TUNEL Staining
The slices were prepared as per methods described above. Briefly, the slices were treated with proteinase K at 37°C for 25 min and with 0.1% Triton for 20 min at 37°C. Then, TUNEL staining was conducted following the manufacturer's instructions (Roche, Basel, Switzerland). Stained positive cells were calculated in each field of the slice. Six areas of each section were randomly selected and recorded under a microscope, and then calculated using the ImageJ version 1.5 software.

Fluoro-Jade C (FJC) Staining
FJC staining to detect neuronal degeneration was performed as per methods reported previously (Liu et al., 2019a). Briefly, brain sections were immersed in 1% NaOH/80% ethanol and sequentially rinsed in 70% ethanol for 2 min, and then immersed in 0.06% potassium permanganate solution for 10 min. Next, sections were placed in a 0.0001% solution of FJC (Millipore, Darmstadt, Germany), which was solubilized in 0.1% acetic acid for 30 min. After rinsing the sections with distilled water, they were dried at 50°C for 10 min. Sections were then imaged by fluorescence microscopy (Leica-DMI8). Frontiers in Pharmacology | www.frontiersin.org February 2021 | Volume 11 | Article 610734 5 ELISA At 24 h after SAH, the rat brain tissue homogenates were obtained and centrifuged for 20 min (4°C, 12,000 × g). The supernatant was harvested and kept at −80°C until use. IL-18, IL-10, and TNF-α levels in the brain tissue lysates were detected with ELISA kits (R&D Systems, Minneapolis, MN, United States) according to the manufacturer's instructions. The samples were detected by spectrometry using a microplate reader. Cytokine concentrations were determined by constructing a standard curve.

Statistical Analysis
All data are expressed as mean ± standard deviation. Statistical analyses were performed using the SPSS version 19.0 software (SPSS, Inc., Chicago, IL, United States). The Student's t-test or Mann-Whitney U test were used to compare two groups after testing the data for normality. Multiple groups were compared by using one-way or two-way analysis of variance with the Bonferroni test. A p-value (p) < 0.05 was considered statistically significant.
Time-Course of Endogenous RVD1, FPR2, and A20 Expression After SAH Levels of endogenous RVD1 in the left hemisphere were detected by ELISA. The data showed the commencement of a gradual decline of RVD1 levels at 6 h after SAH, with the most significant decrease at 24 h (p < 0.05; Figure 1B). Endogenous protein expression of FPR2 was evaluated by western blotting and IF staining. Compared to the sham group, expression of both FPR2 and A20 was upregulated at 6 h after SAH and peaked at 24 h ( Figure 1C-E). Double immunofluorescence staining showed that both FPR2 and A20 were highly expressed in the microglia ( Figure 1F,G), meanwhile A20 was expressed at low levels in the astrocytes and neurons after SAH (Supplementary Figure S2B).

Administration of RVD1 Reduces Brain Edema and Improves Neurological Functions at 24 h after SAH
To investigate the effect of exogenous RVD1 on EBI after SAH, three doses of RVD1 (0.1, 0.3, and 1.0 μg/kg) were administered after SAH. As shown in Figure 2A-C, there were significantly lower neurological scores, higher levels of EB exfiltration, and BWC in the SAH + vehicle group than those in the sham group (p < 0.05). In contrast, after RVD1 administration at doses of 0.3 and 1.0 μg/kg, EB exfiltration and BWC were significantly decreased, and neurological deficits were improved at 24 h after SAH. The H&E-stained slices of the cortex showed that RVD1 administration significantly ameliorated histological damage at doses of 0.3 and 1.0 μg/kg compared to that in the SAH + vehicle group (p < 0.05; Figure 2E). The level of RVD1 in the rat brain tissue was significantly increased in both the sham and SAH groups at 24 h after administration of 0.3 μg/kg RVD1 (p < 0.05; Figure 2D and Supplementary Figure S2A). Based on the above-mentioned results, we selected 0.3 μg/kg as the optimal dose in subsequent experiments.

RVD1 Inhibition of NLRP3 Inflammasome and Microglia Activation Reduces Inflammation after SAH
Activation of immune cells and the release of inflammatory factors are hallmarks of neuroinflammation. We performed IF staining for CD68 and MPO to identify activated microglia and neutrophils, respectively. The result showed that the numbers of CD68 − , MPO-, and NLRP3positive cells were markedly increased at 24 h after SAH. RVD1 treatment significantly reduced the numbers of CD68 − , MPO-, and NLRP3-positive cells in the ipsilateral cortex compared to those in the SAH + vehicle group (p < 0.05; Figure 3A-D). Immunohistochemical staining revealed that Iba-1 and caspase-1p20 were also significantly increased at 24 h after SAH, whereas RVD1 administration reversed these increases ( Figure 3E). SAH increased the expression of the proinflammatory cytokines IL-18 and TNF-α. In contrast, RVD1 treatment downregulated the expression of IL-18 and TNF-α but upregulated that of the anti-inflammatory factor IL-10 ( Figures 3F-H).

RVD1 Decreases the Expression of MMP-9, Upregulates Tight Junction Proteins, and Attenuates BBB Disruption at 24 h after SAH
MMP-9 was highly expressed in the collapsed vessels at 24 h after SAH. MMP-9 expression in the vascular tissues was significantly suppressed after RVD1 injection, and vascular morphology was restored in the cortex ( Figure 4A). Furthermore, RVD1 upregulated tight junction protein expression (occludin-5, claudin, and ZO-1) and reduced MMP-9 compared to the corresponding expression levels in the SAH + vehicle group ( Figure 4B-G).

RVD1 Suppresses Neutrophil Migration at 24 h after SAH and Promotes Neutrophil Apoptosis at 72 h after SAH
Neutrophils are key immune cells that mediate the inflammatory response. To investigate the regulatory effect of RVD1 on neutrophils after SAH, we detected ICAM-1 expression in microvascular endothelial cells and neutrophil apoptosis in the cortex by IF staining (Figure 5A,B). ICAM-1 expression was significantly increased in the microvascular endothelium at 24 h after SAH. RVD1 treatment suppressed the expression of ICAM-1 ( Figure 5A). Interestingly, we found that RVD1 administration increased neutrophil apoptosis in the cortex at 72 h after SAH ( Figure 5B). However, this modulatory effect of RVD1 on neutrophils was reversed after WRW4 injection.

RVD1 Reduces Apoptosis and Neuronal Degeneration after SAH, and WRW4 Reverses the Neuroprotective Effects of RVD1
FJC-and TUNEL-positive cells were markedly increased in the cerebral cortex after SAH. Consistently, the Bcl-2 protein level decreased dramatically, whereas Bax protein was increased. RVD1 administration significantly reduced neuronal apoptosis and neuronal degeneration at 24 h after SAH. However, blocking of FPR2 with WRW4 significantly attenuated the effect of RVD1 against apoptosis and neurodegeneration (p < 0.05; Figure 6A-G). WRW4 also exacerbated neurological deficits and brain edema (p < 0.05; Figure 6H,I).
In contrast, the expression levels of p-NF-κB p65, NLRP3, cleaved caspase-1, IL-Iβ, and MMP-9 were significantly down-regulated compared to those in the SAH + vehicle group (Figures 7A-C, Frontiers in Pharmacology | www.frontiersin.org February 2021 | Volume 11 | Article 610734 8 Figure 8A-I). Double IF staining results confirmed that RVD1 treatment significantly reduced NLRP3 expression in the microglia compared to that in the SAH + vehicle group ( Figure 8J). By blocking FPR2 with WRW4, the effects of RVD1 were abolished at 24 h after SAH (p < 0.05; Figures 7A-C, 8A-J).

DISCUSSION
In this study, we evaluated the role and explored the potential mechanisms of RVD1 in EBI after SAH. The results revealed that endogenous expression of RVD1 was decreased, whereas FPR2 and A20 expression levels were increased in a time-dependent manner and peaked at 24 h, after SAH. FPR2 and A20 were colocalized in the microglia. We also showed that intravenous RVD1 treatment (0.3 or 1.0 μg/kg) could improve neurofunction, reduce brain edema, and alleviate BBB disruption after SAH in rats. RVD1 treatment down-regulated NLRP3 expression in microglia and ICAM-1 expression in vascular endothelial cells, inhibited microglial activation and neutrophil infiltration, significantly increased the expression of the anti-inflammatory molecule A20, promoted neutrophil apoptosis, and ameliorated neuronal degeneration. WRW4, an FPR2 inhibitor, abolished the effects of RVD1 neuroprotection and anti-inflammation. Overall, our data indicate that RVD1 improves neurofunction, mitigates inflammation, protects the BBB partially via the FPR2/A20 pathway, and deactivates the NLRP3 inflammasome in EBI after SAH.
Inflammation triggers BBB disruption, cell death, and oxidative stress in EBI after SAH (Geraghty et al., 2019). Microglia and neutrophils are key immune cells involved in the inflammatory response in CNS inflammation-related diseases, such as hypoxicischemic brain injury and SAH (Z. Xu et al., 2019b;Yao and Kuan, 2020). FPR2, a member of the G protein-coupled receptor family, plays an important role in host defense and cellular debris clearance (Weiss and Kretschmer, 2018). FPR2 is abundantly expressed in neutrophils and can serve as a target for regulation of neutrophil apoptosis and enhancement of the resolution of inflammation (Filep and El, 2009;Dahlgren et al., 2016). Notably, RVD1 exhibited antiinflammatory effects and accelerated inflammation resolution by binding to FPR2 with high affinity (Basil and Levy, 2016;Isopi et al., 2020). We observed that FPR2 co-localized with microglia, which was consistent with findings of a previous study (Guo et al., 2016). This suggests that microglia and neutrophils can be used as targets of RVD1 for SAH treatment. Our results showed that RVD1 suppressed microglial activation and limited neutrophil infiltration while inhibiting the release of inflammatory cytokines TNF-α, IL-18, and IL-1β, thereby increasing anti-inflammatory cytokine IL-10. These results agree with those of a former study (Liu et al., 2019a).
Previously, the resolution of inflammation was considered a passive procedure (Tabas and Glass, 2013). However, emerging studies have revealed that pro-resolving lipid mediators mediate the active resolution of inflammation, although the underlying mechanisms remain poorly understood (Serhan, 2014). In this study, neutrophils were labeled with MPO, and the number of TUNEL-positive MPO cells significantly increased and exhibited nuclear collapse in immunofluorescence staining. The results indicated that RVD1 not only limited neutrophil infiltration, but also promoted neutrophil apoptosis after SAH. Furthermore, we found that high expression of ICAM-1 in vascular endothelial cells after SAH was suppressed by RVD1 treatment. Inhibition of ICAM-1, a key molecule regulating neutrophil adhesion and infiltration, can reduce neutrophil adhesion and infiltration (DiStasi and Ley, 2009). This reveals that RVD1 restriction of neutrophil infiltration may be mediated through inhibition of ICAM-1. While the potential mechanism by which RVD1 promoted neutrophil apoptosis was not explored in this study, this mechanism might be related to the activation of the FPR2/JNK/caspase3 pathway in neutrophils (Cooray et al., 2013).
Zinc finger protein A20 is encoded by the TNFAIP3 gene. As a ubiquitin-editing enzyme, A20 regulates intracellular signaling from pattern recognition receptors to NF-κB via ubiquitin modification, which inhibits the activation of NF-κB and release of IL-1β. A20 plays a crucial role in anti-inflammation and improvement of cell survival (Priem et al., 2020). Previous studies showed that overexpression of A20 reduced acute inflammation in intracerebral hemorrhage and ischemic stroke (Zhan et al., 2016;Perga et al., 2020). We observed high expression of A20 in microglia, but low expression in astrocytes and neurons, and its expression peaked 24 h after SAH. While the cellular localization of A20 in SAH has not been previously reported, A20 is predominantly expressed in neurons and microglia in a mouse model of intracerebral hemorrhage, with its expression peaking at  3 days after intracerebral hemorrhage (Meng et al., 2017). Expression of A20 may vary due to differences between the models; in our rat SAH model, hemorrhage was induced by puncturing large blood vessels on the brain surface, whereas in the ICH model, hemorrhage was induced by injection of autologous blood slowly into the brain parenchyma. Therefore, the inflammatory response initiation in SAH may be more rapid, intense, and with more immune cell involvement than that in ICH. We observed upregulation of A20 expression after RVD1 treatment, which was abolished after WRW4 blocked the FPR2 receptor, suggesting that A20 was a downstream molecule of FPR2.
NLRP3/caspase 1/IL-1β activation induces pyroptosis, a novel form of programmed cell death (Martinon et al., 2002). A growing body of evidence has demonstrated that NLRP3 plays an important inflammatory role in EBI after SAH. It has been reported that a specialized pro-resolving lipid mediator negatively regulates the NLRP3 inflammasome via the NF-κB pathway (Lopategi et al., 2019;Wang et al., 2020). In the present study, NLRP3 was expressed in the microglia and was significantly upregulated at 24 h after SAH. RVD1 significantly decreased the expression of phosphorylated NF-κB and NLRP3, caspase-1, and IL-1β after SAH, However, WRW4 abolishes this effect. A previous study has suggested that A20 is an upstream molecule that inhibits NLRP3 activation (Duong et al., 2015;Voet et al., 2018). In the present study, RVD1 upregulation of A20 may have been involved in regulation of NLRP3 expression.
Pro-inflammatory factors act on death receptors to trigger a caspase-dependent pathway that cleaves Bcl-2 and activates proapoptotic proteins, including Bax, which are involved in mediating neuronal apoptosis (Duris et al., 2018). We found that RVD1 treatment promoted Bcl2 expression, inhibited Bax, and reduced neuronal apoptosis. As our results show that RVD1 protects the BBB, inhibits immune cell infiltration and activation, and significantly decreases inflammatory factors, RVD1 may exert its anti-apoptotic effect by reducing inflammation. RVD1 has also been shown to protect astrocytic mitochondria and reduce reactive oxygen species, thereby reducing neuronal apoptosis in mice of traumatic brain injury (Ren et al., 2020). The specific antiapoptotic mechanism of RVD1 will be addressed in future studies.
There are several limitations to this study. We cannot exclude the fact that other mechanisms are involved in RVD1-mediated alleviation of EBI after SAH. First, regulation of neuroinflammation typically involves a complex signaling network, such as microglial polarization, which is important in neuroinflammation after SAH . Here, we demonstrated that RVD1 inhibited SAH-induced microglial activation but its effect on the microglial polarization was not determined. Second, cerebral vasospasm with delayed cerebral ischemia remains an important factor affecting the poor prognosis after SAH (Neifert et al., 2020). More recently, it was shown that RVD1 relaxed vascular smooth muscles and attenuated vasoconstriction, as well as enhanced perfusion recovery in ischemia injury (Sansbury et al., 2020). Therefore, further studies are warranted to determine the mechanisms of RVD1 in SAH.
In conclusion, we demonstrated that RVD1 attenuated inflammation-mediated BBB disruption and improved neurological deficits in the rat SAH model. This protective effort of RVD1 was, to some extent, partially mediated by the FPR2/A20 pathway and inhibition of the NLRP3 inflammasome activation. Therefore, RVD1 may serve as a potential new drug and FPR2 as a novel pharmacological target for the treatment of SAH.

DATA AVAILABILITY STATEMENT
The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.

ETHICS STATEMENT
The animal study was reviewed and approved by Southern Medical University Ethics Committee.

AUTHOR CONTRIBUTIONS
CW, WL, and CD were responsible for the conception and design of the study. CW, SG, HF, and BW conducted the experiments, FJ, JL, HS, DF, GL, XZ, and XL participated in data collection and analysis. SS and NZ wrote the main manuscript text. XH and CD critically reviewed and revised the paper. All authors contributed to the study and manuscript preparation and approved the submitted version.